Related Experiment Video
Updated: Mar 1, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Regulatory Consequences of "Brexit" for the Development of Medicinal Products
E L Jackson1, P Feldschreiber2, A Breckenridge3
1London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK.
Abstract:
The United Kingdom voted in a referendum in June 2016 to leave the European Union (EU) after 45 years of membership. Among the many political, social, and scientific consequences are those for the regulation of health care products. No longer will the efficacy, safety, and quality of medicines in the United Kingdom be subject to an EU regulatory framework. The European Medicines Agency (EMA), which is currently located in London, will move elsewhere in Europe. The pharmaceutical industry will reassess its commitment to the UK health scene.
More Related Videos
Related Concept Videos
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Preclinical Development: Overview

